What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Jeffrey Sparks MD MMSc jeffsparks
3 years 6 months ago
These findings suggest a pathogenic link between airway inflammation in bronchiectasis and RA-related autoantibodies
TheDaoIndex KDAO2011
3 years 6 months ago
Prof van Lear noted 5-10% of pts have D2T RA; the highest risk factor is low socieconomic status. D2T RA have higher comorbidities and healthcare utilization #EULAR2022 @rheumnow https://t.co/PhPjhksyI4 https://t.co/JCByho4ubk
Jeffrey Sparks MD MMSc jeffsparks
3 years 6 months ago
Associations with RA-BR (n=57 cases) compared to RA-no lung disease controls (n=36)
⬆️⬆️⬆️RF level (OR 4.4)
⬆️⬆️ ACPA level (OR 3.5)
⬆️older age at RA onset (OR 1.37 per 10 years)
⬇️ BMI (OR 0.94 per kg/m2) (i.e., higher risk in underweight)
🚫 associations: sex, smoking pk-yrs
David Liew drdavidliew
3 years 6 months ago
Difficult to treat rheumatoid arthritis is expensive - to the health system, but also to society #EULAR2022 @RheumNow https://t.co/eM2Ih3kGL7
Aurelie Najm AurelieRheumo
3 years 6 months ago
🧨 Factors associated w/ Pulmonary Embolism in ORAL surveillance:
⚡️history of VTE ⚡️antidepressant use
⚡️BMI≥30
⚡️corticosteroid use
⚡️male gender
⚡️age ≥65
⚡️Hx of Hypertension
⚡️hormonal ttmt use
POS0239 #EULAR2022 @RheumNow https://t.co/pT6MDAUbjH
TheDaoIndex KDAO2011
3 years 6 months ago
Prof van Lear reviews #EULAR ’s 11 points to consider for difficult to treat RA (D2T RA) published here https://t.co/zOLiMChjx8 #EULAR2022 @rheumnow (1/n) https://t.co/mVjJ5A1VkW
Dr. Rachel Tate uptoTate
3 years 6 months ago
Dr. E. Loza reminds #EULAR2022 that it is important to measure response of patients when using clinical guidelines for treatment! It will help us adapt guidelines for the future to help patients. @RheumNow https://t.co/pMkpsMH44U
Dr. Antoni Chan synovialjoints
3 years 6 months ago
The reference is at https://t.co/Auwrimc0jt
Richard Conway RichardPAConway
3 years 6 months ago
Eun et al. South Korean population based study. n=138,592 RA patients. aHR dementia 1.19 (95%CI 1.16–1.23), Alzheimers 1.21 (95%CI 1.67-1.25), Vascular dementia 1.10 (95%CI 0.99-1.21) @RheumNow #EULAR2022 OP0271 https://t.co/URNYnYzuF6
Richard Conway RichardPAConway
3 years 6 months ago
Razmjou et al. Survival in RA-ILD patients with lung transplant comparable to other cohorts. Not surprisingly UIP pattern trended to worse outcome HR 7.13, p=0.06 @RheumNow #EULAR2022 OP0275 https://t.co/RJ1nMkHwRh https://t.co/iUENMhqiX3
Alberta Hoi alberta_hoi
3 years 6 months ago
Case reports of tofacitinib efficacy for calcinosis over last couple of years. Benefits were relatively quickly (within 3m) reported by Jiri Vencovsky #eular2022
Alberta Hoi alberta_hoi
3 years 6 months ago
Lisa Rider suggests that calcinosis is more commonly seen in JDM than adults maybe the result of the more prominent vasculopathy and IFN signature. #EULAR2022
David Liew drdavidliew
3 years 6 months ago
Always satisfying to see the big plenary hall in full flight #EULAR2022 @RheumNow https://t.co/DkzZCFvFw7
Dr. John Cush RheumNow
3 years 6 months ago
SLE trials update
Translating targeted therapy from bench to bedside has been more problematic in SLE than other autoimmune diseases.
https://t.co/xmYbgOplsm https://t.co/QUrtwAJqNl
Poster Hall